CA-GLOBALLOGIC-INC.
9.11.2021 12:02:05 CET | Business Wire | Press release
GlobalLogic Inc. ,1 a Hitachi Group company and leader in Digital Engineering, today announced the availability of its enhanced Microservices Accelerator, a comprehensive and pluggable digital microservices development platform. Developed by GlobalLogic, this technology is used in conjunction with the company’s Digital Engineering services to greatly simplify and accelerate the design, configuration, and deployment of Microservices platforms – which are the most commonly deployed architectures in creating new digital experiences.
Notably, the Microservices Accelerator is currently the foundation platform for many GlobalLogic clients including EyeCare Partners , the leading healthcare service provider for optometry and ophthalmology; Petplan , the most comprehensive pet health care insurance in North America; and DISA Global Solutions , the leading provider of safety, compliance, and screening services.
Part of GlobalLogic’s Digital Accelerators product offerings, the Microservices Accelerator provides a complete solution that includes a project configurator and a set of pluggable modules that perform the most common Non-Functional Requirements (NFRs) required by any microservices-based deployment. The latest release introduces advanced capabilities including CloudEvents support, security framework upgrades, and ETag support to enhance caching capabilities.
Digital Accelerator Key Value Proposition
Driving the accelerator’s development were Independent Software Vendors (ISVs), enterprises, and startup company needs. As more companies move their product offerings to cloud-native platforms, developers seek codified tools that can efficiently address and automate common, time-consuming processes. Early results have shown a savings of up to 75 person months for a typical large-size deployment project, which means significantly reduced time to market, a more reliable and repeatable process, and increased ROI.
“Having deployed many such platforms over the last couple of years, GlobalLogic has established a strong body of knowledge that we have included in this toolset — ranging from enterprise-scale capabilities to best practices. Our clients are already shaving off months from the bootstrap, and reducing overall implementation costs and effort with our solution,” said Piyush Jha , SVP & Chief of Technology and Strategy (APAC), GlobalLogic.
“Microservices is a great architectural paradigm that takes modularity to the next level and, in many ways, is fundamental for achieving the massive scale requirements of modern software,” said Deepak Gupta , SVP & Global Head of Technology Practices, GlobalLogic. “This accelerator is an out-of-box solution that allows engineers to set up complex architectures in a single day, rather than the months typically required. Moreover, it provides a required guardrail to operate within, and reduces the possibilities of human error — which is essential to being successful with this programming paradigm.”
Inter-Company Deployment
As part of Hitachi’s acquisition of GlobalLogic, the accelerator technology will be utilized in Hitachi's services and solutions going forward.
“Hitachi Application Services Division is excited to leverage the GlobalLogic Accelerators in its service delivery schema,” said Emi Goto, Senior Director, Application Services Division, Hitachi, Ltd. “The growth of our Lumada business will be accelerated in the expanding Digital Transformation market by combining the innovativeness of GlobalLogic's Experience Design and Chip-to-Cloud software engineering with Hitachi's enterprise application delivery experiences in mission critical systems.”
GlobalLogic’s Microservices Accelerator supports both containers and functions as a service-based deployment model across cloud hyperscalers Microsoft Azure, AWS, and Google Cloud Platform (GCP).
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
1 July 14, 2021 News Release "Hitachi Completes Acquisition of GlobalLogic” https://www.hitachi.com/New/cnews/month/2021/07/f_210714.pdf
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005358/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom